Dyne Therapeutics, Inc. (DYN) stock
DYNNasdaqPharmaceutical PreparationsFiscal year ends December 31
$17.01−0.98 (-5.45%)
Close on Nov 12, 2026Market cap $3.18BP/E –Yield –
Dyne Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Dyne Therapeutics's ebitda for the twelve months ending Sep 30, 2026 was -$617.87M. For fiscal 2025 it was -$466.14M. The highest annual figure on record is -$13.56M in fiscal 2019.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$466.14M | – |
| FY2024 | Dec 31, 2024 | -$342.21M | – |
| FY2023 | Dec 31, 2023 | -$240.49M | – |
| FY2022 | Dec 31, 2022 | -$169.28M | – |
| FY2021 | Dec 31, 2021 | -$148.94M | – |
| FY2020 | Dec 31, 2020 | -$57.95M | – |
| FY2019 | Dec 31, 2019 | -$13.56M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$196.47M | – |
| Q2 FY2026 | Jun 30, 2026 | -$181.06M | – |
| Q1 FY2026 | Mar 31, 2026 | -$124.73M | – |
| Q4 FY2025 | Dec 31, 2025 | -$115.61M | – |
| Q3 FY2025 | Sep 30, 2025 | -$113.39M | – |
| Q2 FY2025 | Jun 30, 2025 | -$115.29M | – |
| Q1 FY2025 | Mar 31, 2025 | -$121.87M | – |
| Q4 FY2024 | Dec 31, 2024 | -$96.66M | – |
| Q3 FY2024 | Sep 30, 2024 | -$105.17M | – |
| Q2 FY2024 | Jun 30, 2024 | -$71.56M | – |
| Q1 FY2024 | Mar 31, 2024 | -$68.77M | – |
| Q4 FY2023 | Dec 31, 2023 | -$67.29M | – |
| Q3 FY2023 | Sep 30, 2023 | -$61.87M | – |
| Q2 FY2023 | Jun 30, 2023 | -$66.34M | – |
| Q1 FY2023 | Mar 31, 2023 | -$45.05M | – |
| Q4 FY2022 | Dec 31, 2022 | -$39.74M | – |
| Q3 FY2022 | Sep 30, 2022 | -$41.88M | – |
| Q2 FY2022 | Jun 30, 2022 | -$52.26M | – |
| Q1 FY2022 | Mar 31, 2022 | -$35.36M | – |
| Q4 FY2021 | Dec 31, 2021 | -$51.62M | – |
| Q3 FY2021 | Sep 30, 2021 | -$42.47M | – |
| Q2 FY2021 | Jun 30, 2021 | -$29.97M | – |
| Q1 FY2021 | Mar 31, 2021 | -$24.90M | – |
| Q4 FY2020 | Dec 31, 2020 | -$28.38M | – |
| Q3 FY2020 | Sep 30, 2020 | -$13.32M | – |
| Q2 FY2020 | Jun 30, 2020 | -$8.48M | – |
| Q1 FY2020 | Mar 31, 2020 | -$7.70M | – |
| Q4 FY2019 | Dec 31, 2019 | -$5.32M | – |
| Q3 FY2019 | Sep 30, 2019 | -$3.53M | – |
See a number that looks wrong?